Twist Bioscience Launches Full Length Unique Dual Index Adapters to Enable PCR-free Whole Genome Sequencing
31 Outubro 2023 - 9:00AM
Business Wire
Adds to robust offering of NGS tools enabling
exome sequencing, whole genome sequencing, RNA sequencing and
methylation detection
Enables multiplexing and high throughput
sequencing
New offering expands and complements Twist’s
portfolio of universal adapters
Twist Full Length UDI Adapters to be
highlighted at ASHG 2023
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced the launch of Twist
Full Length Unique Dual Index Adapters to enable PCR-free whole
genome sequencing (WGS) and multiplexing at scale.
The new adapters include unique dual indexing (UDI) sequences,
along with flow cell binding site and sequencing priming site,
enabling NGS library preparation in a single ligation step and
eliminating the need for PCR and amplification. This can streamline
the library preparation workflow, reduce hands-on time, and also
eliminate the sequence errors and artifacts potentially introduced
during PCR amplification. The product comes with 1536 UDIs, which
are barcoded indexes that allow for the tracking of individual
samples. This is critical for researchers who multiplex, running
tests on many samples at once to lower per-sample costs and
increasing efficiency, such as core labs and scientists studying
population genetics. Twist Full Length UDI Adapters enable
researchers to track and run up to 1536 samples through a single
sequencing run, while maintaining data integrity by identifying
errors that occur from index hopping or well to well contamination
prior to data analysis.
“As we grow our customer base, we are continuing to expand our
offering to meet our customers’ needs, whether that is whole
genome, exome or RNA sequencing,” said Emily M. Leproust, Ph.D.,
CEO and co-founder of Twist Bioscience. “With Twist Full Length UDI
Adapters, we can enable PCR-free whole genome sequencing for our
customers pursuing that approach, including our customers in Europe
where PCR-free WGS has gained traction.”
Twist Full Length Unique Dual Index Adapters
Twist Full Length UDI Adapters add to Twist’s portfolio of
universal adapter systems, which include Twist Universal Adapter
System and Twist High Throughput Universal Adapter System. Twist
Full Length UDI Adapters include 1,536 indexes and come in
automation-friendly configurations of 96 or 384 sets of adapters,
giving customers the ability to multiplex anywhere between two and
1,536 samples. The full length UDI adapters can be used in various
NGS workflows and for PCR-free whole genome sequencing.
Presence at American Society of Human Genetics (ASHG)
Twist will have a booth at the American Society of Human
Genetics Annual Meeting 2023 in Washington, D.C., where the new
offering will be highlighted at the Twist in-booth (booth #322)
presentation “Twist NGS Library Prep & Enrichment Solutions” on
Thursday, November 2 at 11:00 AM ET.
Twist will also present “Portfolio of RNA Sequencing Tools”
in-booth on Friday, November 3 at 11:00 AM ET. In addition, the
poster “Targeted sequencing of 50+ pathogenic repeat expansions
using Twist target enrichment and PacBio HiFi sequencing” will be
available for viewing on Saturday, November 4 from 2:15-4:45 PM
ET.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including statements regarding the ability of Twist Full
Length UDIs to enable PCR-free WGS and multiplexing at scale, are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause Twist
Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
ability to achieve the expected benefits of Twist Bioscience’s
workforce reduction and reduced investments in DNA data storage;
the ability to attract new customers and retain and grow sales from
existing customers; the ability of Twist to achieve sufficient
revenue to achieve or maintain positive cash flow from operations
or profitability in any given period; risks and uncertainties of
rapidly changing technologies and extensive competition in
synthetic biology that could make the products Twist Bioscience is
developing obsolete or non-competitive; uncertainties of the
retention of significant customers; the ability of Twist Bioscience
to successfully integrate acquired companies and to achieve
expected benefits from acquisitions; supply chain and other
disruptions caused by the COVID-19 pandemic or otherwise; risks of
third party claims alleging infringement of patents and proprietary
rights or seeking to invalidate Twist Bioscience’s patents or
proprietary rights; and the risk that Twist Bioscience’s
proprietary rights may be insufficient to protect its technologies.
For a description of the risks and uncertainties that could cause
actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on August 7,
2023 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231031498715/en/
For Investors: Angela Bitting SVP, Corporate Affairs
925-202-6211 abitting@twistbioscience.com
For Media: Amanda Houlihan Communications Generalist
774-265-5334 ahoulihan@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Twist Bioscience (NASDAQ:TWST)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024